antigen negative These recommendations were made based on the risk of hepatitis B reactivation due to core antibody and surface antigen status and the specific DMARD being initiated and are consistent with the updated American Association for the Study of Liver Diseases guidance Persistent hypogammaglobulinemia without infection In the setting of persistent hypogammaglobulinemia without infection, continuation of rituximab therapy for patients at target is conditionally recommended over